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AN EXPERIMENTAL STUDY OF THE EFFECTS OF SUBCUTANEOUS
IMPLANTATION OF ANDROGENS AND ESTROGENS
ON HUMAN SKIN*
WALTER B. SHELLEY, M.D., PH.D. AND HARRY J. HTJRLEY, JR. M.D.1-
It has long been known that hormones are of great importance in the develop-
ment and maintenance of normal human skin and its appendages. At puberty,
during pregnancy and at the climacterie, striking changes have been observed in
the growth of body hair, in sebaceous, apocrine and even eccrine sweat gland
function, as well as the state of the epidermis and corium (1). Furthermore, the
disappearance or recrudescence of various dermatologic disorders with endocri-
nologic alterations is well known. Despite such evidence, however, the precise
relationship of the various known hormones of human skin is, in the main,
unknown. The results of animal studies have not been satisfactorily reproduced
in man, probably because of species variation and dosage differences (2). Signifi-
cant changes in human skin have been observed only after long term high dosage
hormonal therapy in clinical disease such as breast carcinoma (3). In such in-
stances, however, histologic and control observations were usually lacking, and
the underlying disease process may have altered the observed tissues.
Of all the available hormonal substances, androgens and estrogens have been
implicated most often for the changes in human skin believed to be induced
endocrinologically. The source of these hormones need not always be the gonads,
for it is known that the adrenal glands produce both androgenic and estrogenic
principles. The persistence of some sexual characteristics in the castrate has been
accounted for on this basis.
Because of the above reasons, it was decided to examine the effects of androgens
and estrogens experimentally on human skin. In a previous study (4), failure to
observe dramatic effect in man after the topical and systemic administration of
hormones might be explained on the basis of relatively low dosage levels, lack of
absorption and short term trials. The avoidance of these difficulties was para-
mount in this study, however, and long-term subcutaneous implantation of
hormone pellets was employed as the method of administration in an effort to
obviate them. Dosage varied from one to three pellets in the site to be observed,
and they were left in place for periods ranging from one to five months. The
hormone was intimately in contact with vessels, appendages and other structures
of the skin. Dosage was highest in this immediate area, of course, and diminished
with increasing distance from the pellet. The axillary skin was chosen as the
test region because it contained the full variety of cutaneous appendages found
in human skin, viz., eccrine, apocrine, sebaceous glands, and hair.
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TABLE I
No. of Men Hormone(s) Used and Dosage Biopsy After Comments
1 Progynon—25 mgm. 1 month
1 Progynon—25 mgm. 2 months
1 Progynon—25 mgm. 3 months
1 Progynon—25 mgm. 4 months
Progynon—25 mgm. 5 months Two of these subjects developed bilat-
eral gynecomastia and one subject de-
veloped unilateral gynecomastia on
the treated side.
1 Oreton—75 mgm. 1 month
1 Oreton—75 mgm. 2 months
1 Oreton—75 mgm. 3 months
1 Oreton—75 mgm. 4 months
4 Oreton—75 mgm. 5 months
2 Progynon—75 mgm. 3 months Bilateral gynecomastia developed in
both subjects.
2 Oreton—150 mgm. 3 months
2 Oreton—225 mgm. 1 month
1 Oreton—225 mgm. 3 months
1 Oreton—150 mgm. in 3 months Bilateral gynecomastia.
one axilla vs. Progy-
non—75 mgm. in op-
posite axilla.
2 Oreton—75 mgm. in 3 months Bilateral gynecomastia developed in
one axilla vs. Progy- both subjects.
non—75 mgm. in op-
posite axilla.
I
_______________________________
MATERIALS AND METHODS
Twenty-seven normal healthy adult male volunteers between the ages of 20
and 45 years were selected for this study. 75 mgm. pellets of Oreton F (Testos-
terone. USP, Schering) and 25 mgm. pellets of Progynon (Estradiol—Schering) *
were implanted subcutaneously in axillary skin as outlined in the table below.
Both treated and control (without pellet implantation) axillae were shaved at
the beginning of the study, and were compared clinically for eccrine and apocrine
sweating, and hair growth at weekly intervals for two months, then monthly,
until sectioned for biopsy. Generous scalpel biopsies of both treated and control
axillae were taken at this time,t serially sectioned and stained with hematoxylin
and eosin. A total of 54 biopsies, each containing an average of 300 serial sec-
tions, were secured for study. In addition, in many instances, gross examination
of this skin and its appendages with the stereoscopic microscope (2—20 X) was
* Generously supplied by G. Kenneth Hawkins, M.D., Division of Clinical Research,
Schering Corporation, Bloomfield, New Jersey.
t Itwas found that the estradiol pellets were grossly unchanged even after five months.
They were removed at the time of biopsy. In contrast the testosterone pellets disintegrated
in one month, and were not to be seen after two months.
SUBCUTANEOUS IMPLANTATION OF ANDROGENS AND ESTROGENS 157
FIG. 1. Histologic view of estradiol prillet site, five months after implantation in the
axilla. The clear area in the lower half of the field is the space oceispied hy the pellet which
was removed at hiopsy. Note the normal apocrine glands which have been in eontinuons
intimate contact with the estradiol for five months. Despite the absence of effect on the
apoerine glands and other skin strnetnres, this hormone implant did produce gynecomastia
on the same side. Mag. X 25.
utilized to detect possible over-all variation in the structures that might he
obsenre histologically.
RESULTS AND DISCUSSION
On both treated and control sides we were unable to detect significant varia-
tions in the quantity or quality of the eccrine, apocrine or sebaceous secretion,
in the type or rate of axillary hair growth, or in the character of the axillary skin
itself. Furthermore, visualization of gross specimens under stereoscopic magnifi-
cation and histologic examination of the biopsy material failed to reveal appre-
ciable differences in any of these structures from treated and control axillae.
A rather frequent finding, however, was the development of gynecomastia in
the subjects with estrogen (Progynon) implantation. The appearance of this
change was apparently related to length of time the pellets were left in place and
to dosage. Three of the subjects with 25 mgm. Progynon pellet implants devel-
oped gynecomastia after about four months. In two of these subjects, the change
was bilateral, while in a third homolateral gynceomastia was observed, apparently
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indicating local lymphatic spread of the drug. All of the men with 75 mgm.
Progynon implants, whether the opposite axilla was treated with Oreton or was
left untreated, developed bilateral gynecomastia within three months. This
phenomenon demonstrates that there was no failure of absorption of the hor-
monal substances from the implanted pellets.
Emphasis should be placed on the fact that in this study the hormone-contain-
ing pellet was actually in contact with many of the structures of the skin (Fig.
1). Using the implant technic, the local concentration of the hormone in the skin
was far higher than that which could be achieved by any systemic or topical
dosage. The failure of these large "local doses" of estrogen and androgen to pro-
duce change in any of the adult skin structures, in the face of observable hormonal
effects (gynecomastia), indicates that elevations of androgen or estrogen con-
centrations in the skin are without effect, despite the fact that these very sub-
stances may be responsible for the continued activity and normal function of this
skin and its appendages. Furthermore, these findings support the view that
neutralization of the effect of one hormone cannot be achieved by the admin-
istration of another. Certainly the estrogen levels in the axillary skin of our sub-
jects with Progynon implants far exceeded the physiologic levels of androgen
normally present.
SUMMARY
It has been shown that androgens and estrogens, implanted in the axilla in
pellet form for periods up to five months, failed to produce demonstrable change
in the axillary skin or its appendages.
Gynecomastia was regularly observed in subjects treated with the estrogen
implants, and its appearance varied directly with dosage employed and length
of exposure to the drug.
These observations indicate that androgens and estrogens have no direct local
effect on normal adult male human skin.
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